ADMA Biologics Inc - Stock Price History | ADMA

Historical daily share price chart and data for ADMA Biologics Inc since 2021 adjusted for splits. The latest closing stock price for ADMA Biologics Inc as of September 24, 2021 is 1.25.
  • The all-time high ADMA Biologics Inc stock closing price was 12.50 on November 06, 2014.
  • The ADMA Biologics Inc 52-week high stock price is 3.11, which is 148.8% above the current share price.
  • The ADMA Biologics Inc 52-week low stock price is 1.15, which is 8% below the current share price.
  • The average ADMA Biologics Inc stock price for the last 52 weeks is 1.90.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ADMA Biologics Inc Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.7877 3.9350 4.5900 1.5000 1.9500 -51.25%
2019 4.1274 2.6200 5.3900 2.6100 4.0000 67.36%
2018 4.9253 3.3000 6.8500 2.1700 2.3900 -25.55%
2017 3.7640 4.9800 5.4600 2.0600 3.2100 -37.30%
2016 6.2083 7.8800 8.6000 4.1500 5.1200 -36.56%
2015 9.2362 11.4500 11.4500 7.7500 8.0700 -27.75%
2014 9.5722 7.5000 12.5000 7.3000 11.1700 43.21%
2013 7.9069 8.5500 8.5500 6.8000 7.8000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.170B $0.042B
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71